Hefu China released its 2026 semi-annual report, showing a first-half net loss attributable to shareholders of about 7.4992 million yuan, compared with a loss of about 7.3382 million yuan in the same period last year. The company achieved first-half operating revenue of about 339 million yuan, down 7.87 percent year on year. Hefu China said the performance change was mainly due to the domestic macro environment and the full implementation of centralized procurement policies in various regions, which led to lower procurement prices for hospital customers and shrinking order volumes, causing revenue from its IVD intensive business to decline year on year. The company continued to invest in iterative research and development of its own ACME products and market expansion, with MetaWei moving from technical validation into clinical use, while also optimizing supply chain management. Operating profit improved, and the decline in performance this period has narrowed significantly compared with the same period last year.
Cowealth Medical China Co.Ltd.IVD intensive business revenue declined due to lower procurement prices and shrinking order volumes from hospital customers.
